U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Links from MedGen

Items: 1 to 20 of 243

1.
Factors Associated with Postoperative Recurrence in Stage I to IIIA Non–Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation: Analysis of Korean National Population Data
Kyu Yean Kim, Ho Cheol Kim, Tae Jung Kim, Hong Kwan Kim, Mi Hyung Moon, Kyongmin Sarah Beck, Yang Gun Suh, Chang Hoon Song, Jin Seok Ahn, Jeong Eun Lee, Jae Hyun Jeon, Chi Young Jung, Jeong Su Cho, Yoo Duk Choi, Seung Sik Hwang, Chang Min Choi, Seung Hun Jang, Jeong Uk Lim, Korean Association for Lung Cancer, Korea Central Cancer Registry
Cancer Res Treat. 2025 Jan; 57(1): 83–94. Published online 2024 Jul 10. doi: 10.4143/crt.2024.073
PMCID:
PMC11729316
ArticlePDF–1.4M
2.
Plasma-Based Comprehensive Genomic Profiling DNA Assays for Non-Small Cell Lung Cancer: A Health Technology Assessment
Ontario Health (Quality)
Ont Health Technol Assess Ser. 2024; 24(8): 1–306. Published online 2024 Nov 7.
PMCID:
PMC11650780
ArticlePDF–5.8M
3.
Multiplex digital profiling of DNA methylation heterogeneity for sensitive and cost-effective cancer detection in low-volume liquid biopsies
Yang Zhao, Christine M. O’Keefe, Jiumei Hu, Conor M. Allan, Weiwen Cui, Hanran Lei, Allyson Chiu, Kuangwen Hsieh, Sonali C. Joyce, James G. Herman, Thomas R. Pisanic, Tza-Huei Wang
Sci Adv. 2024 Nov 22; 10(47): eadp1704. Published online 2024 Nov 22. doi: 10.1126/sciadv.adp1704
PMCID:
PMC11584010
ArticlePDF–4.8M
4.
Advances and future directions in ROS1 fusion-positive lung cancer
Mary C Boulanger, Jaime L Schneider, Jessica J Lin
Oncologist. 2024 Nov; 29(11): 943–956. Published online 2024 Aug 23. doi: 10.1093/oncolo/oyae205
PMCID:
PMC11546726
ArticlePDF–5.6M
5.
A Prospective Observational Study on Analyzing Lung Cancer Gene Mutation Variant Allele Frequency (VAF) and Its Correlation with Treatment Efficacy
Yusuke Shinozaki, Kei Morikawa, Hirotaka Kida, Hiroshi Handa, Hisashi Saji, Seiji Nakamura, Yoshiharu Sato, Yumi Ueda, Fumihiko Suzuki, Ryo Matoba, Masamichi Mineshita
Int J Mol Sci. 2024 Nov; 25(21): 11694. Published online 2024 Oct 30. doi: 10.3390/ijms252111694
PMCID:
PMC11546704
ArticlePDF–1.2M
6.
Detection of EGFR mutations in patients with suspected lung cancer using paired tissue-plasma testing: a prospective comparative study with plasma ddPCR assay
Lynn Yim-Wah Shong, Jun-Yang Deng, Hoi-Hin Kwok, Nerissa Chui-Mei Lee, Steven Cee-Zhung Tseng, Lai-Yun Ng, Wilson Kwok-Sang Yee, David Chi-Leung Lam
Sci Rep. 2024; 14: 25701. Published online 2024 Oct 28. doi: 10.1038/s41598-024-76890-0
PMCID:
PMC11514293
ArticlePDF–1.6M
7.
Proteolysis Targeting Chimera Agents (PROTACs): New Hope for Overcoming the Resistance Mechanisms in Oncogene-Addicted Non-Small Cell Lung Cancer
Nicoletta Cordani, Daniele Nova, Luca Sala, Maria Ida Abbate, Francesca Colonese, Diego Luigi Cortinovis, Stefania Canova
Int J Mol Sci. 2024 Oct; 25(20): 11214. Published online 2024 Oct 18. doi: 10.3390/ijms252011214
PMCID:
PMC11508910
ArticlePDF–742K
8.
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Hsu-Yuan Chen, Chia-Hung Chen, Wei-Chih Liao, Yu-Chao Lin, Hung-Jen Chen, Te-Chun Hsia, Wen-Chien Cheng, Chih-Yen Tu
BMC Pulm Med. 2024; 24: 517. Published online 2024 Oct 16. doi: 10.1186/s12890-024-03336-8
PMCID:
PMC11481380
ArticlePDF–1.8M
9.
A random survival forest-based pathomics signature classifies immunotherapy prognosis and profiles TIME and genomics in ES-SCLC patients
Yuxin Jiang, Yueying Chen, Qinpei Cheng, Wanjun Lu, Yu Li, Xueying Zuo, Qiuxia Wu, Xiaoxia Wang, Fang Zhang, Dong Wang, Qin Wang, Tangfeng Lv, Yong Song, Ping Zhan
Cancer Immunol Immunother. 2024 Dec; 73(12): 241. Published online 2024 Oct 3. doi: 10.1007/s00262-024-03829-9
PMCID:
PMC11448477
ArticlePDF–6.8M
10.
CircLIFRSA/miR-1305/PTEN axis attenuates malignant cellular processes in non-small cell lung cancer by regulating AKT phosphorylation
Meina Jiang, Huihui Bai, Shuai Fang, Chengwei Zhou, Weiyu Shen, Zhaohui Gong
Mol Cancer. 2024; 23: 208. Published online 2024 Sep 28. doi: 10.1186/s12943-024-02120-w
PMCID:
PMC11438201
ArticlePDF–6.1M
11.
Proteomic Stratification of Prognosis and Treatment Options for Small Cell Lung Cancer
Zitian Huo, Yaqi Duan, Dongdong Zhan, Xizhen Xu, Nairen Zheng, Jing Cai, Ruifang Sun, Jianping Wang, Fang Cheng, Zhan Gao, Caixia Xu, Wanlin Liu, Yuting Dong, Sailong Ma, Qian Zhang, Yiyun Zheng, Liping Lou, Dong Kuang, Qian Chu, Jun Qin, Guoping Wang, Yi Wang
Genomics Proteomics Bioinformatics. 2024 Apr; 22(2): qzae033. Published online 2024 Apr 18. doi: 10.1093/gpbjnl/qzae033
PMCID:
PMC11423856
ArticlePDF–4.5M
12.
Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study
Niels Reinmuth, Oscar Juan-Vidal, Dariusz Kowalski, Maciej Bryl, Anna Kryzhanivska, David Vicente, Zsolt Horváth, Gabriella Gálffy, Eszter Csánky, Zsolt Pápai Székely, Ihor Vynnychenko, Jon Armstrong, Tapashi Dalvi, Mingchao Xie, Sonia Iyer, Yashaswi Shrestha, Haiyi Jiang, Igor Bondarenko
Clin Cancer Res. 2024 Sep 13; 30(18): 4055–4067. Published online 2024 Jul 17. doi: 10.1158/1078-0432.CCR-24-0013
PMCID:
PMC11393542
ArticlePDF–2.7M
13.
Complete response in a lung adenocarcinoma with pleural metastases initially treated with gefitinib and switched to osimertinib after cerebral oligo-progression with unknown T790M mutation: a case report and review of literature
Mariem Hachlaf, Sihame Lkhoyaali, Wydad Nadir, Hajar Lemsyeh, Brahim El Ghissassi, Hind Mrabti, Saber Boutayeb, Hassan Errihani
J Med Case Rep. 2024; 18: 374. Published online 2024 Aug 8. doi: 10.1186/s13256-024-04706-w
PMCID:
PMC11308728
ArticlePDF–762K
14.
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial
Solange Peters, Shirish M. Gadgeel, Tony Mok, Ernest Nadal, Saadettin Kilickap, Aurélie Swalduz, Jacques Cadranel, Shunichi Sugawara, Chao-Hua Chiu, Chong-Jen Yu, Mor Moskovitz, Tomohiro Tanaka, Rhea Nersesian, Sarah M. Shagan, Margaret Maclennan, Michael Mathisen, Vijay Bhagawati-Prasad, Cheick Diarra, Zoe June Assaf, Venice Archer, Rafal Dziadziuszko
Nat Med. 2024; 30(7): 1923–1932. Published online 2024 Jun 19. doi: 10.1038/s41591-024-03008-4
PMCID:
PMC11271410
ArticlePDF–4.2M
15.
The Evolving Scenario of ES-SCLC Management: From Biology to New Cancer Therapeutics
Pamela Trillo Aliaga, Ester Del Signore, Valeria Fuorivia, Gianluca Spitaleri, Riccardo Asnaghi, Ilaria Attili, Carla Corvaja, Ambra Carnevale Schianca, Antonio Passaro, Filippo de Marinis
Genes (Basel) 2024 Jun; 15(6): 701. Published online 2024 May 27. doi: 10.3390/genes15060701
PMCID:
PMC11203015
ArticlePDF–2.9M
16.
Response to dabrafenib plus trametinib on a rare BRAF mutation (V600_W604 deletion–insertion R) in an advanced non‐small cell lung cancer patient
Akiko Tamura, Ryoko Inaba Higashiyama, Tatsuya Yoshida, Yaya Satozono, Yuichiro Ohe
Thorac Cancer. 2024 Jun; 15(18): 1454–1456. Published online 2024 May 20. doi: 10.1111/1759-7714.15330
PMCID:
PMC11194117
ArticlePDF–1.3M
17.
Blocking the angiopoietin-2–dependent integrin β-1 signaling axis abrogates small cell lung cancer invasion and metastasis
Lydia Meder, Charlotte Isabelle Orschel, Christoph Julius Otto, Mirjam Koker, Johannes Brägelmann, Meryem S. Ercanoglu, Sabrina Dähling, Anik Compes, Carolin Selenz, Marieke Nill, Felix Dietlein, Alexandra Florin, Marie-Lisa Eich, Sven Borchmann, Margarete Odenthal, Raquel Blazquez, Frank Hilberg, Florian Klein, Michael Hallek, Reinhard Büttner, H. Christian Reinhardt, Roland T. Ullrich
JCI Insight. 2024 May 22; 9(10): e166402. Published online 2024 May 22. doi: 10.1172/jci.insight.166402
PMCID:
PMC11141935
ArticlePDF–6.7M
18.
Tumor marker-based RecistTM is superior to RECIST as criteria to predict the long-term benefits of targeted therapy in advanced non-small-cell lung cancer with driver gene mutations
Kai Xiong, Yi Yang, Yanan Yang, Zhengbo Wang, Yun Liu, Hong Duo, Xinya Yuan, Yao Xiao, He Xiao, Xueqin Yang
Neoplasia. 2024 Jul; 53: 101006. Published online 2024 May 17. doi: 10.1016/j.neo.2024.101006
PMCID:
PMC11127532
ArticlePDF–4.4M
19.
Diagnostic leukapheresis reveals distinct phenotypes of NSCLC circulating tumor cells
Lisa-Marie Rieckmann, Michael Spohn, Lisa Ruff, David Agorku, Lisa Becker, Alina Borchers, Jenny Krause, Roisin O’Reilly, Jurek Hille, Janna-Lisa Velthaus-Rusik, Niklas Beumer, Armin Günther, Lena Willnow, Charles D. Imbusch, Peter Iglauer, Ronald Simon, Sören Franzenburg, Hauke Winter, Michael Thomas, Carsten Bokemeyer, Nicola Gagliani, Christian F. Krebs, Martin Sprick, Olaf Hardt, Sabine Riethdorf, Andreas Trumpp, Nikolas H. Stoecklein, Sven Peine, Philipp Rosenstiel, Klaus Pantel, Sonja Loges, Melanie Janning
Mol Cancer. 2024; 23: 93. Published online 2024 May 8. doi: 10.1186/s12943-024-01984-2
PMCID:
PMC11077784
ArticlePDF–1.7M
20.
Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer
Sandra Salvi, Vincenzo Fontana, Simona Boccardo, Domenico Franco Merlo, Edoardo Margallo, Stefania Laurent, Anna Morabito, Erika Rijavec, Maria Giovanna Dal Bello, Marco Mora, Giovanni Battista Ratto, Francesco Grossi, Mauro Truini, Maria Pia Pistillo
Cancer Immunol Immunother. 2012 Sep; 61(9): 1463–1472. Published online 2012 Feb 9. doi: 10.1007/s00262-012-1211-y
PMCID:
PMC11029051
ArticlePDF–747K

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
You are here: NCBI > Literature > PubMed Central (PMC)
Support Center